Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LATIFY
2022-000493-26Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Jun 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Ceralasertib + durvalumab with Docetaxel (2 arms). Primary endpoint: Overall survival. Started Jun 2022; status: active.
02
Drugs
ceralasertibdurvalumabdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-000493-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000493-26.